Clinical bottom line
Cerebral amyloid angiopathy (CAA) is increasingly recognized as a contributor to cognitive impairment, distinct yet overlapping with Alzheimer’s disease pathology. Early intervention strategies targeting vascular health, cognitive rehabilitation, and risk factor modification show promise but remain largely hypothesis-generating due to limited direct evidence. Neuroimaging biomarkers such as peak width of skeletonized mean diffusivity (PSMD) may aid early detection and monitoring of cognitive decline in CAA. Clinicians should maintain vigilance for cognitive symptoms in patients with CAA and consider multidisciplinary approaches while awaiting more definitive trials.
What the evidence shows
CAA is characterized by amyloid-β deposition in cerebral small vessels, leading to microvascular dysfunction, microbleeds, and ischemic injury that contribute to cognitive decline (van Etten Ellis et al., 2014). Cognitive impairment in CAA often manifests as executive dysfunction and slowed processing speed, distinct from the memory-predominant deficits of Alzheimer’s disease (Saydaliev et al., 2025). Neuroimaging advances, including diffusion tensor imaging metrics such as PSMD, have emerged as sensitive biomarkers correlating with vascular cognitive impairment severity in CAA, potentially enabling earlier diagnosis and monitoring (Zanon et al., 2022).
Early intervention strategies remain exploratory. Vascular risk factor control (e.g., hypertension management) is a plausible target given the vascular pathology underlying CAA-related cognitive impairment (van Etten Ellis et al., 2014). Cognitive rehabilitation tailored to executive dysfunction and vascular cognitive profiles may offer benefit, although direct evidence in CAA populations is sparse. Pharmacologic interventions are complicated by bleeding risk; antithrombotic management requires careful balancing of ischemic and hemorrhagic risks (Kelly et al., 2021). Emerging data suggest that Parkinsonism and cognitive impairment can co-occur in CAA without lobar hemorrhage, underscoring the heterogeneity of clinical presentations and the need for individualized approaches (Forteza et al., 2019).
Despite these insights, no randomized controlled trials have yet established the efficacy of specific early interventions for cognitive impairment in CAA. The under-reported burden of CAA-related cognitive decline and its overlap with Alzheimer’s disease pathology complicate clinical management and research design (Mehndiratta et al., 2025).
Caveats and uncertainty
The evidence base for early intervention in CAA-associated cognitive impairment is limited and largely observational or derived from related vascular cognitive impairment literature. The heterogeneity of CAA presentations and overlap with Alzheimer’s disease pathology challenge clear diagnostic categorization and therapeutic targeting (Saydaliev et al., 2025). Neuroimaging biomarkers like PSMD require further validation in prospective cohorts before routine clinical use (Zanon et al., 2022).
Pharmacologic interventions are constrained by the high risk of intracerebral hemorrhage in CAA, limiting options such as anticoagulation or antiplatelet therapy (Kelly et al., 2021). Cognitive rehabilitation and vascular risk factor management strategies lack large-scale trials specifically in CAA populations, so their efficacy remains uncertain. Additionally, the natural history of cognitive decline in CAA is variable, complicating assessment of intervention impact.
How this may change practice
Clinicians should maintain a high index of suspicion for cognitive impairment in patients with known or suspected CAA, particularly when executive dysfunction or vascular cognitive profiles predominate. Incorporating advanced neuroimaging biomarkers such as PSMD into diagnostic workups may facilitate earlier detection and monitoring, pending further validation.
Early and aggressive management of vascular risk factors remains a prudent approach to potentially mitigate progression of cognitive impairment in CAA. Multidisciplinary care involving neurology, neuropsychology, and rehabilitation specialists may optimize cognitive outcomes through tailored cognitive rehabilitation, although evidence is preliminary.
Antithrombotic therapy decisions require individualized risk-benefit assessment given hemorrhagic risks in CAA. Clinicians should counsel patients on the current uncertainties and the importance of close follow-up. Participation in clinical trials investigating early interventions in CAA-related cognitive impairment should be encouraged to build the evidence base.